The Microdosing Collective has stated it is committed to a world where sub-perceptible microdosing of psychedelics is legal, accessible and safe.
With a rise in interest in the use of psychedelics microdoses – such as psilocybin – for conditions such as depression and anxiety, The Microdosing Collective will be working to promote the regulation of microdoses as over-the-counter products.
The collective suggests that one potential path forward is to regulate microdoses of psychedelics as over-the-counter wellness supplements under the purview of the Food and Drug Administration (FDA) or a state-based system.
Microdosing Collective co-founder and microdosing expert, Paul Austin, commented: “Over the past few years, there have been incredible strides made to provide psychedelic substances within a legal and regulated framework.
“Unfortunately, none of these initiatives have created policy specific to the adult use of microdosing psychedelics. We seek to change that.”
Currently, a number of clinical studies are being carried out in the US on the benefits of psychedelics for conditions such as post traumatic stress disorder (PTSD), addiction and treatment-resistant depression.
The collective highlights that most FDA-approved research studies focus on the clinical outcomes of using consciousness-altering doses of psychedelics during guided sessions, and that state-regulated models only allow access to quantities of psychedelics that dramatically shift consciousness.
With a lack of regulatory pathways to accessing sub-perceptible doses of psychedelics, The Microdosing Collective is seeking to create a legal pathway for microdosing psychedelics, not as a medical treatment but as a wellness supplement.
The collective has stated that it believes Americans who microdose should not have to procure their supplements through illicit market operators.
Co-founder of the non-profit and long-time drug policy attorney, Joshua Kappel, stated: “The Collective estimates at least 600,000 people in the US actively microdose psychedelic medicines. The problem we are addressing is that none of these products are legal or guaranteed to be safe.
“Our goal is to educate the public through the Microdosing Collective about the benefits of a legal microdosing market.”
Co-founder of Microdosing Collective and CEO & co-founder of Into The Multiverse, an education-first ecosystem on mushrooms, Alli Shaper, commented: “The largest barrier to access for microdosing stems from its current classification as a Schedule I drug, which legally labels psilocybin as highly addictive with no medical benefit.
“Research shows quite the opposite. When used correctly, with the right education and support, microdosing can have a massive positive impact on people’s lives. The use of these supplementation protocols is on the rise for both mental health and human optimisation with thousands of people reaping the benefits.
“Our goal is to provide a safe and legal channel for microdosing supplements, which is really a form of harm reduction and mitigation of the risks that come from cross contamination and incorrect dosing via underground channels.”
[activecampaign form=52]
